8-K: Kura Oncology Reports Strong KOMZIFTI Launch, Outlines 2026 Milestones

Kura Oncology announced preliminary KOMZIFTI revenue of $2.1 million for its initial commercial period and detailed key development milestones for 2026.

Summary

• Launched KOMZIFTI (ziftomenib), the first and only once-daily, oral menin inhibitor approved for adults with relapsed or refractory (R/R) NPM1-mutated acute myeloid leukemia (AML).
• Reported preliminary KOMZIFTI net product revenue of $2.1 million for the period from its first commercial sale on November 21, 2025, through December 31, 2025.
• Received $195 million in milestone payments under a collaboration agreement with Kyowa Kirin in the fourth quarter of 2025.
• Estimated non-cash collaboration revenue for the fourth quarter of 2025 between $15 million to $17 million.
• Held $667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• KOMZIFTI was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A recommended treatment option for adults with R/R NPM1-m AML in November 2025.
• Presented favorable safety and encouraging antileukemic activity data for ziftomenib in combination with venetoclax and azacitidine at the 67th Annual Meeting of the American Society of Hematology (ASH 2025).
• Initiated the Phase 3 KOMET-017 trial in September 2025, evaluating ziftomenib in combination with chemotherapy regimens in newly diagnosed NPM1-m or KMT2A-r AML.
• Presented compelling preliminary data from farnesyl transferase inhibitor (FTI) programs (tipifarnib and darlifarnib) at the 2025 European Society for Medical Oncology (ESMO) Congress.
• Anticipates non-cash collaboration revenue recognition of $45 million to $55 million in 2026.
• The current cash position, along with anticipated short-term collaboration payments and product revenue, is expected to support the ziftomenib AML program through topline results in the front-line Phase 3 trial.

Sentiment

Score: 8

Explanation: The filing reports a successful initial commercial launch of a newly approved drug, significant collaboration milestone payments, a strong cash position, and a robust pipeline with clear development milestones for 2026. While safety risks are inherent to oncology drugs and disclosed, the overall tone and content indicate strong positive momentum and financial health.

Positives

• Successful commercial launch of KOMZIFTI, generating $2.1 million in net product revenue in just five weeks of initial availability.
• FDA approval of KOMZIFTI as the first and only once-daily, oral menin inhibitor for R/R NPM1-mutated AML, addressing a high unmet medical need.
• Inclusion of KOMZIFTI in NCCN Clinical Practice Guidelines as a Category 2A recommended treatment, validating its clinical utility.
• Strong financial position with $667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• Significant milestone payments of $195 million received from the Kyowa Kirin collaboration in Q4 2025.
• Positive preliminary data reported for ziftomenib in combination therapies and for farnesyl transferase inhibitor programs, indicating pipeline strength.
• Advancement of ziftomenib into Phase 3 trials for newly diagnosed AML, expanding its potential market.
• Cash runway is expected to support the ziftomenib AML program through topline results in the front-line Phase 3 trial, reducing immediate financing concerns.

Risks

• Differentiation Syndrome (DS): Can be fatal, occurred in 26% of R/R NPM1-m AML patients (13% Grade 3, 2 fatal cases). Occurred in 25% of all AML patients treated with KOMZIFTI monotherapy, with 4 fatal cases in KMT2A-rearranged AML patients (KOMZIFTI is not approved for this indication).
• QTc Interval Prolongation: Can cause QTc interval prolongation, reported in 12% of R/R NPM1-m AML patients (8% Grade 3). QTcF was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients.
• Embryo-Fetal Toxicity: Based on animal findings and mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman.
• Fatal Adverse Reactions: Occurred in 4% of patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death.
• Serious Adverse Reactions: Reported in 79% of patients, with common serious reactions including infection (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).
• Drug Interactions: Potential interactions with strong or moderate CYP3A4 inhibitors/inducers, gastric acid reducing agents, and drugs that prolong the QTc interval.
• Infertility: Based on animal findings, KOMZIFTI may impair fertility in females and males of reproductive potential.
• Market Competition: Risks associated with market competition for KOMZIFTI.
• Market Acceptance and Commercialization: Risks associated with the market acceptance and commercialization success of KOMZIFTI.
• Clinical Trial Conduct: Risks associated with the conduct of preclinical studies and clinical trials.
• Regulatory Approval: Risk that product candidates may not receive regulatory approval.
• Unexpected Adverse Side Effects: Potential for KOMZIFTI or product candidates to have unexpected adverse side effects.
• Additional Financing: Risk that Kura may not be able to obtain additional financing.
• Collaboration Success: Risk that the collaboration with Kyowa Kirin is unsuccessful.
• Drug Development and Commercialization: General risks associated with discovering, developing, and commercializing safe and effective drugs.

Future Outlook

Kura Oncology anticipates accelerating U.S. uptake and driving quarter-over-quarter growth in KOMZIFTI net product revenue in 2026. The company plans to advance ziftomenib development through various combination trials and into non-AML indications, including Phase 3 trials for newly diagnosed AML. Darlifarnib development will see expansion cohorts initiated and preliminary data presentations. The pipeline includes advancing next-generation menin inhibitors for diabetes, cardiometabolic diseases, and solid tumors. The current cash position, along with anticipated collaboration payments and product revenue, is expected to fund the ziftomenib AML program through topline results of the front-line Phase 3 trial.

Management Comments

• "Following the landmark FDA approval of KOMZIFTI on November 13, 2025, we are executing a robust commercial launch to drive rapid adoption and market share growth." Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology.
• "With KOMZIFTIs compelling efficacy, favorable safety profile and ease of use, we believe that we are strongly positioned for success and encouraged by the first few weeks of our commercial launch." Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology.
• "Our comprehensive development strategy advances ziftomenib into combinations and earlier lines of therapy, including newly diagnosed patients with NPM1 mutations, KMT2A rearrangements, and FLT3 mutations, supported by our expanding pipeline programs and solid cash position." Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology.
• "We are excited to deliver meaningful impact for patients throughout 2026 and beyond." Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology.

Industry Context

Kura Oncology's launch of KOMZIFTI, the first and only oral menin inhibitor for R/R NPM1-mutated AML, positions it as a significant player in a niche but devastating blood cancer market with limited treatment options. The expansion into combination therapies and earlier lines of treatment, alongside the development of next-generation inhibitors and farnesyl transferase inhibitors, aligns with the broader industry trend towards precision medicine and targeted therapies for oncology and other diseases like diabetes and cardiometabolic conditions. The inclusion in NCCN guidelines further solidifies its standing within the medical community, indicating strong clinical acceptance.

Stakeholder Impact

• Shareholders: Positive impact due to successful drug launch, strong initial revenue, significant milestone payments, robust cash position, and clear pipeline advancement, potentially leading to increased share value.
• Patients (R/R NPM1-mutated AML): Direct positive impact with the availability of KOMZIFTI, the first and only oral menin inhibitor, offering a new treatment option for a devastating blood cancer.
• Employees: Positive impact from company growth, successful product launch, and continued pipeline development, indicating job security and potential for expansion.
• Kyowa Kirin (Collaborator): Positive impact from the successful launch and milestone payments, reinforcing the value of their collaboration.
• Healthcare Providers: New treatment option (KOMZIFTI) added to NCCN guidelines, providing a clear recommendation for use in R/R NPM1-m AML.

Next Steps

• Accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML.
• Drive quarter-over-quarter growth in KOMZIFTI net product revenue.
• Present updated KOMET-007 data evaluating combination with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML in the first half of 2026.
• Publish ven/aza combination data in R/R NPM1-m AML in the first half of 2026.
• Present preliminary data from KOMET-008 cohort evaluating combination with gilteritinib in R/R NPM1-m/FLT3-m AML in the second half of 2026.
• Advance enrollment of KOMET-017 Phase 3 trials for newly diagnosed AML, including combinations with intensive and non-intensive chemotherapy, in 2026.
• Advance enrollment of KOMET-007 cohort evaluating combination with 7+3 and quizartinib in newly diagnosed NPM1-m/FLT3-m AML (quad) in 2026.
• Expand ziftomenib to non-AML indications in 2026, including an ongoing Phase 1a dose escalation trial evaluating combination with imatinib in gastrointestinal stromal tumors.
• Initiate expansion cohorts of darlifarnib and cabozantinib in advanced renal cell carcinoma (RCC) (Phase 1b) in the first half of 2026.
• Present preliminary data from darlifarnib and adagrasib in KRASG12C-mutated solid tumors in the first half of 2026.
• Present updated dose-escalation data from darlifarnib and cabozantinib in advanced RCC (Phase 1a) in the second half of 2026.
• Explore opportunities to evaluate additional darlifarnib indications and combination agents in 2026.
• Publish preclinical menin inhibitor data on diabetes in the second half of 2026.
• Advance KO-7246, a next-generation menin inhibitor, in IND-enabling studies for diabetes and cardiometabolic diseases in 2026.
• Advance preclinical development of a next-generation menin inhibitor development candidate for use in combination therapy for solid tumors in 2026.

Key Dates

Recommendation

The filing details a highly successful initial commercial launch of KOMZIFTI, a first-in-class FDA-approved drug, generating $2.1 million in just five weeks. This, coupled with a substantial $195 million in collaboration milestone payments and a robust cash position of $667.3 million, significantly de-risks the company's near-term financial outlook and provides a long runway for its extensive pipeline. The clear roadmap for 2026, including advancing ziftomenib into Phase 3 trials and exploring new indications, demonstrates strong strategic execution and future growth potential. The inclusion of KOMZIFTI in NCCN guidelines further validates its clinical utility. While inherent drug risks are disclosed, the operational and financial performance, combined with pipeline progress, indicates a strong investment opportunity.

Keywords

Kura Oncology, KURA, KOMZIFTI, ziftomenib, AML, acute myeloid leukemia, NPM1-mutated, menin inhibitor, biopharmaceutical, FDA approval, oncology, clinical trials, KOMET-007, KOMET-017, darlifarnib, farnesyl transferase inhibitor, precision medicine, cancer treatment, financial results, Q4 2025, 2026 milestones